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Background The Trial to Reduce Insulin Dependent Diabetes Mellitus in the Geneti-
cally at Risk (TRIGR) is the first multicenter international type 1 diabetes (T1D) pre-
vention trial to be undertaken. A unique feature of TRIGR has been recruitment of
eligible pregnant women and enrollment of newborns for long-term follow-up
assessments.
Purpose Our purpose is to summarize the recruitment and retention strategies
used to conduct TRIGR from the perspective of the study coordinators.
Methods TRIGR was designed to test whether weaning to formula containing
hydrolyzed versus intact cow’s milk protein would be efficacious in decreasing risk
for development of T1D-associated autoantibodies and T1D among infants identi-
fied to be at increased risk for T1D based on their human leukocyte antigen (HLA)
profile and family history. Multiple strategies tailored to local issues were required to
enroll and follow the target number of infants.
Results This study was conducted in the United States, Canada, Australia, and 12
countries in Europe. Of the 5606 mothers registered worldwide, 5000 of their
infants were randomized. Of these, 2159 were HLA eligible and enrolled in the 8-
month intervention and 10-year follow-up phases of this study. The TRIGR study
met the accrual goal after 4.7 years of recruitment, 2.7 years longer than projected
initially. Challenges included difficulty in finding fathers with T1D, a higher than
expected rate of premature delivery among T1D mothers, and implementation of
new privacy regulations mid-trial. The majority of participants were recruited from
primary care antenatal clinics located near the study centers and from a general hos-
pital or pediatric center that was affiliated with a TRIGR Study center. Internet and
magazine advertisements were found to be useful for recruitment of families. Alter-
native follow-up strategies are offered to families who wish to reduce or discontinue
participation.
Limitations Our experience is limited to a single international multicenter trial.
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Conclusions TRIGR coordinators played key roles in the recruitment and interven-
tion periods and continue to be instrumental in retaining families and children dur-
ing the 10-year follow-up period for each child. Clinical Trials 2014; 11: 150–158.
http://ctj.sagepub.com
The incidence of type 1 diabetes (T1D) in young
children has been increasing worldwide and is pre-
dicted to continue rising [1]. The cause of T1D is
believed to be a combination of genetic predisposi-
tion and b cell autoimmunity induced early in life
by environmental or lifestyle risk factors. The risk of
developing T1D is higher among children born to
men with T1D than among those whose mother or
sibling has T1D [2]. The environmental or lifestyle
triggers believed to influence the expression of the
disease include viruses such as Coxsackie B, mumps,
and congenital rubella; growth parameters; and
early introduction of foreign dietary proteins during
infancy or childhood [3,4].
International research trials designed to evaluate
prevention approaches for chronic diseases are
essential in order to improve worldwide health. The
large sample size required of prevention trials neces-
sitates effective coordination strategies to recruit
participants from different countries and healthcare
settings [5]. For this reason, the role of study coordi-
nator is especially important during recruitment.
An effective study coordinator must possess the fol-
lowing qualities: (1) excellent interpersonal and
organizational skills to maximize recruitment oppor-
tunities and ensure that the study protocol is fol-
lowed precisely, (2) flexibility to provide maximum
convenience to participating families, and (3) colle-
giality to share successful recruitment strategies with
other study coordinators. Few publications discuss
the challenges of coordinating a pediatric multicen-
ter, international clinical trial. Furthermore, even
less information exists in the literature regarding the
ethical and logistical challenges of recruitment of
unborn children into a double-blind randomized
controlled trial. Incomplete sample size can result in
the inability to conclude whether there is a differ-
ence in outcomes between the treatment groups;
recruitment phase extension adds costs [6].
Reasons reported for nonparticipation in longitu-
dinal studies of children have included the family
moving away from the study center, the child being
diagnosed with a medical problem, lack of interest
or time, difficulty scheduling visits, and family pro-
blems (e.g., parents separated or divorced, loss of
employment) [7]. Liese et al. [8] evaluated the asso-
ciation between demographic characteristics of chil-
dren with diabetes and level of study participation
and reported a decline in participation rate as the
age of the child increased. However, families of
children with T1D more often participated than
those with type 2 diabetes or other diabetes type.
Karlson and Rapoff [9] examined attrition rates
reported in 40 randomized studies of cognitive
behavioral interventions in children with chronic
conditions, including diabetes. Of all families eligi-
ble for a study, 37% refused to participate. The most
common reasons reported for dropping out
included parent being too busy, loss of interest,
technical complications with study procedures, tra-
vel distance, and too many appointments. Janus
and Goldberg [10] compared factors that influenced
participation in a prospective study in families of
children under 1 year of age with and without
chronic illness. During the course of the study,
35.4% of families were lost. The majority of families
with children who had a chronic illness reportedly
dropped out because they were too busy.
The Trial to Reduce Insulin Dependent Diabetes
Mellitus in the Genetically at Risk (TRIGR) study is a
randomized, double-blind trial to evaluate whether
hydrolyzed infant formula compared to cow’s milk-
based formula decreases development of T1D in
children with increased genetic susceptibility [7].
The study is being conducted successfully in 15
countries on three continents (North America, Eur-
ope, and Australia). Our purpose is to summarize the
strategies used by the study coordinators to imple-
ment TRIGR, with a specific focus on communica-
tion, screening, recruitment, and retention, in order
to contribute to a knowledge base for future clinical
trials designed to enroll pregnant women and their
unborn children.
Methods
A full description of the TRIGR study protocol has
been published [7]. The trial was approved by the
Ethics Institutional Review Board (IRB) or Commit-
tee of Human Experimentation in all participating
institutions. Children at increased risk for develop-
ing T1D from the United States, Canada, Australia,
and 12 countries in Europe enrolled in the trial
between May 2002 and December 2006. As new-
borns, they were randomized to receive one of four
color-coded, blinded formulas for use after weaning
from breastfeeding or in the absence of breastfeed-
ing. Two formulas contained the hydrolyzed-protein
test formula (Nutramigen; Mead Johnson
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Nutrition, Evansville, IN, USA) and two contained
the control formula (intact cow’s milk protein for-
mula with Nutramigen (20%) used to mask the taste
and smell differences between the formulas). The
duration of the intervention for each infant was
until at least 6 months of age. Whenever the mother
chose to breastfeed exclusively up to the age of 6
months, she was advised to give the formula there-
after when supplementation was needed until the
age of 8 months. Follow-up visits including dietary
interviews, clinical assessments, and blood sampling
are conducted at 3, 6, 9, 12, 18, and 24 months and
annually thereafter. Consent and dietary forms are
available in 12 different languages.
Sample size calculations were based on previous
family studies that analyzed the occurrence of auto-
antibodies in children with a first-degree relative
with T1D. The sample size estimate of 2800 rando-
mized infants was based on the following assump-
tions: a confidence level of 95%, a statistical power
of 80%, a reduction of 40% in the hazard rate of
T1D in the intervention group, a dropout rate of
20%, and a frequency of 10% exclusive breastfeed-
ing up to the age of 6 months [9]. The children are
monitored for T1D-associated autoantibodies and/
or a diagnosis of clinical T1D until 2017 when all
children will be at least 10 years old. An oral glucose
tolerance test is performed at 6 and 10 years of age
and again at the final study visit for all participating
children who have not had a diagnosis of T1D by
those ages.
The TRIGR study group used available birth rate
and T1D incidence rate data across the world to set
a recruitment target for study sites in each country
[11]. At the beginning of the study, it was estimated
that study personnel would need to recruit 6220
newborns eligible for genetic testing to meet the ori-
ginal goal of 2800 human leukocyte antigen (HLA)-
eligible infants, under the assumption that 55%
would be excluded based on a low risk of developing
T1D. The primary investigators anticipated that
65% of families would be recruited from North
America (USA and Canada) and that the remaining
35% of families would originate from 12 European
countries and Australia. Recruitment began in May
2002 and was expected to continue for 2 years or
until the enrollment target was met. However,
delays in receiving ethical approvals, funding issues,
and problems with customs clearance for shipments
of study formula in some countries resulted in post-
ponement of start-up for some centers. Enrollment
at the target rate of 100 women per month was not
reached until January 2003, 8 months after the start
of recruitment. In June 2003, the eligibility criteria
were revised to include infants born at 35 weeks
gestation and older (previously 36 weeks) due to the
high number of pregnant women with T1D who
had delivered at 35–36 weeks. In May 2004, the
screening target and randomization goal were
revised to 4516 and 2032, respectively, based on a
change in the planned analyses for the primary out-
come measure. Eighteen additional centers were
added in Canada and Europe to bring the final num-
ber of actively enrolling TRIGR centers to 77 by July
2005. Based on the revised target sample size and
enrollment of about 800 participating families dur-
ing the first 2 years, it was projected that revised
sample size target would be met in December 2006,
that is, by extending the accrual period to 4.7 years.
A Recruitment Form was completed for each
family by a member of the study team (Figure 1).
However, this form was not completed for all
families to whom the study was introduced; there-
fore, it is not possible to report the total number of
families contacted. When a family met the primary
inclusion criteria for enrollment, that is, the biologi-
cal parent and/or full sibling of the newborn infant
had T1D as defined by the World Health Organiza-
tion and the infant’s parent or legal guardian gave
signed consent to participate, a registration form
was completed, and the family enrolled. Exclusion
criteria included an older sibling of the newborn
infant participating in TRIGR, multiple gestation,
parents unwilling to feed the infant cow’s milk-
based products, the gestational age of the newborn
\35 weeks, and inability of the family to take part
in this study. Once enrolled, the family was rando-
mized before or immediately after birth so that the
assigned study formula could be provided and con-
tamination with other infant formulas could be
avoided. Eligibility of the infant for the study inter-
vention and follow-up phases was determined after
birth based on the results of HLA assays and a
review of exclusion criteria: the infant received an
infant formula other than breast milk or Nutrami-
gen prior to randomization, the infant had a severe
recognizable illness, randomization did not occur
before the infant was 8 days old, or no sample was
drawn via cord blood or heel stick before 8 days of
age for HLA assays. Infants with eligible HLA-
genotypes remained in the trial; all other infants
were withdrawn from TRIGR. At least 864 families
in each randomized group are expected to complete
the trial [7].
In 2012, we administered a questionnaire to assess
retrospectively study center recruitment resources
and strategies. A study team member at each TRIGR
center who had been present during the recruitment
period was asked to respond to the following ques-
tions about the experience at their center: (1) Was
there sufficient staff during the entire recruitment
period? (2) Was there at least one person on the
study team who was experienced in clinical trial
recruitment? (3) Was someone available at the cen-
ter at all times to answer recruitment telephone
calls? (4) Were recruitment planning meetings held
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Figure 1. Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk (TRIGR) recruitment form.
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before the start of the study? (5) Were recruitment
training meetings held at the study center? (6) What
were the greatest challenges of recruitment?
Organization and data management
The TRIGR study group is divided into regions with
central coordination by the International Central
Coordinating Center located at the University of
Helsinki (Finland) and headed by the study princi-
pal investigator. There are two regional groups: (1)
12 European countries (Czech Republic, Estonia,
Finland, Germany, Hungary, Italy, Luxembourg, The
Netherlands, Poland, Spain, Sweden, and Switzer-
land) and Australia, with the regional coordinating
center in Helsinki, Finland, and (2) North America
with a coordinating center in Pittsburgh, Pennsylva-
nia, for the United States, and another in London,
Ontario, for Canada. Of 77 study centers participat-
ing in this study, 50 are in Europe, 3 are in Australia,
18 are in Canada, and 6 are in the United States. A
Nutrition Special Investigator and Epidemiologist
and a Nutrition Fellow, both in Finland, and a Nutri-
tion Coordinator in North America monitored diet-
ary compliance during the intervention period.
TRIGR data are managed by the Data Management
Unit (DMU) located at the Pediatrics Epidemiology
Center at the University of South Florida, Tampa,
Florida. The DMU developed a web-based data sys-
tem that has provided web-based randomization
and electronic data entry as well as online study
operation documents and progress reports accessible
by authorized study team members.
Role of the TRIGR study coordinators
Every country has at least one national coordinator.
When there are several study centers in a country,
there is also a local coordinator at each study center.
In addition, one or more study monitors manage
international coordination between the European
countries and Australia. Each national coordinator
works with the local coordinators to organize and
maintain the day-to-day operations of the study
center, to communicate information to the study
team, and to motivate, encourage, and help the
team to solve problems. At the beginning of this
study, the national coordinators prepared a regional
recruitment plan and assisted with implementation
of the intervention at the study centers in their
region. The national coordinators/monitor trained
the center coordinators and organized regular tele-
phone conferences or meetings to discuss recruit-
ment and retention strategies and to determine the
most effective tools for recruitment and retention at
their center. The national coordinators, supported
by the study monitor in Europe, remain responsible
for ensuring study center adherence to the study
protocol, updating ethical approval, monitoring
data entry, conducting audits, developing data col-
lection forms and letters to families, assisting with
updates to the TRIGR Manual of Operations in order
to address the needs of study sites in each country,
and providing fiscal management. The national
coordinators communicate directly with DMU per-
sonnel and the TRIGR International Coordinating
Center. National coordinators work with local coor-
dinators and laboratory technicians to ensure that
blood samples are sent to the central laboratory in
Helsinki every 3 months for analysis.
Each study center is staffed with nurses and physi-
cians with experience in pediatrics, diabetes, neona-
tology or obstetrics, laboratory technicians and/or
research assistants, and, primarily during the inter-
vention period, dietitians. Local coordinators were
responsible for recruitment of mothers and infants;
this responsibility included development of a cen-
ter-specific recruitment plan, training of staff at
local delivery hospitals, direct communication with
families to schedule and conduct interviews and
examinations, and assistance with informing
families of test results. Local coordinators currently
are responsible for retention of participating families
and children under follow-up at the local center.
Results
The TRIGR study team exceeded its revised recruit-
ment goal of 2032 HLA eligible infants in September
2006. Of the 5606 mothers who were registered,
5000 were randomized. The remaining 606 partici-
pants were excluded prior to randomization due to
ineligibility (e.g., preterm delivery, miscarriage,
family withdrew consent) or randomization in error.
Of the 2159 infants who were HLA eligible and
remained in the study for intervention and follow-
up, 43% were from North America and 57% from
Europe/Australia, which differed from the initial
estimates of 65% and 35%, respectively. About half
the infants had only mothers with T1D (49%); for
34%, only the fathers had T1D (Table 1). As of 31
March 2013, 302 (14%) of 2159 participating
families and children were classified as dropouts; 36
were considered to be lost to follow-up. Families
who no longer are participating fully in scheduled
follow-up procedures may agree to annual telephone
contact by study coordinators to determine the pri-
mary outcome of T1D status for their children.
Based on Recruitment Forms completed, 2795 out
of 6836 families (41%) recruited in Canada, Europe,
and the United States were from hospital-based
antenatal clinics or primary antenatal clinics. Other
recruitment sources included adult diabetes clinics,
obstetric clinics, delivery hospitals, and pediatric
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diabetes clinics or doctor’s offices. Recruitment
material was delivered through the Internet (TRIGR
web pages, National Diabetes Association web pages,
etc.), television advertisements, postings in pharma-
cies, and advertisements in journals, magazines, and
newspapers targeted for diabetes professionals, peo-
ple with T1D, and pregnant women. The countries
with the greatest total recruitment were Canada, Fin-
land, and the United States. Participants in Canada
and Finland were recruited mainly from the TRIGR
study center that was affiliated with a general hospi-
tal or pediatric center. In the United States, the
majority of participants were recruited from an
antenatal clinic in a hospital.
Challenges and strategies of recruitment
The recruitment strategies utilized by the TRIGR
study group were developed after the establishment
of recruitment targets and determination of study
center locations but prior to the start of recruitment.
Although the initial intent was to recruit partici-
pants primarily from the area surrounding the study
centers, often a large city where high-volume endo-
crinology and high-risk pregnancy clinics existed,
the target area was expanded in many countries in
order to meet enrollment goals. Expansion of areas
targeted for recruitment required additional ethics
approvals and additional personnel training at
remote locations.
Recruitment strategies used in TRIGR by the study
centers to identify eligible pregnant women and
men with T1D whose partners were pregnant are
shown in Table 2. The Internet and magazine arti-
cles were useful for attracting potential participants
in all regions. In Europe and Australia, the most
effective strategy was face-to-face contact with par-
ents. In North America, articles in magazines that
target pregnant women, such as Fit Pregnancy, Par-
enting, and Prevention, generated many inquiries
from potentially eligible families. An article that
appeared in December 2002 in Parade magazine
(Parade Publications, New York, NY), which has
wide circulation in the United States, yielded the
greatest number of eligible participants across TRIGR
in the United States. In the North American centers,
families received a small gift (e.g., bib, infant cap)
after the baby was born as a token of appreciation
regardless of whether or not the family and infant
remained eligible for this study. In addition, the
annual TRIGR newsletter was sent to families in
North America regardless of eligibility. These items
served to remind families of TRIGR should the first
child not be eligible and the mother become preg-
nant again.
The TRIGR website for study personnel, which
was launched in 2002, provided recruitment pro-
gress reports and minutes from annual Steering
Committee meetings. A link to the TRIGR website
for the public (www.trigr.org in Europe and
www.TRIGRNorthAmerica.org in North America)
Table 1. HLA eligible randomized participants by first-degree relative with T1D by country
Country Parent(s) only with T1D Parent(s) and sibling(s) parents with T1D
Mother only Father only Both Mother only Father only Both Sibling only Total Total percent
Australia 54 34 2 0 0 0 11 101 4.7
Canada 286 162 7 5 5 0 63 528 24.5
Czech Republic 89 59 0 0 0 0 16 164 7.6
Estonia 18 8 3 0 0 0 5 34 1.6
Finland 147 226 2 0 7 0 42 424 19.6
Germany 54 29 4 0 2 0 23 112 5.2
Hungary 18 2 0 0 0 0 3 23 1
Italy 32 11 0 0 1 0 10 54 2.5
Luxembourg 5 1 0 0 0 0 1 7 0.3
Netherlands 25 19 0 0 3 0 7 54 2.5
Poland 56 11 2 0 1 1 23 94 4.4
Spain 36 19 2 0 1 0 2 60 2.8
Sweden 42 37 1 1 2 0 14 97 4.4
Switzerland 3 5 0 0 0 0 5 13 0.6
United States 190 100 6 4 11 0 83 394 18.3
Total 1055 723 29 10 33 1 308 2159 100
Total Percent 48.9 33.5 1.3 0.5 1.5 14.3 100
HLA: human leukocyte antigen; T1D: type 1 diabetes.
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was available on frequently accessed diabetes web-
sites (e.g., Children with Diabetes, Juvenile Diabetes
Research Foundation, and American Diabetes Asso-
ciation), which enhanced study visibility and pro-
vided families with information about the study as
well as center contact information. TRIGR Family
Newsletters were distributed to recruitment sources
and posted on the TRIGR website as a tool to
increase awareness of the study. Study team mem-
bers attended diabetes related functions (e.g., fun-
draising walks) to distribute recruitment materials.
All recruitment materials included a toll-free tele-
phone number and email addresses for all regional
study centers. The study primary investigators also
introduced TRIGR at international scientific meet-
ings to increase awareness among endocrinologists
outside of the immediate study center areas.
The questionnaire that we used to assess recruit-
ment resources and strategies, retrospectively, revealed
that the majority of country coordinators believed
that they had adequate recruitment staff. All of the
country coordinators reported that they had at least
one person on the study team with experience with
recruiting participants for a clinical trial, that some-
one from the study team was available to respond to
recruitment calls at all times, and that recruitment
planning/training meetings were held prior to the
study start. Study coordinators were available at all
times to support the maternity hospital staff and to
collect cord blood samples for HLA typing.
Challenges to recruitment reported by the
national coordinators included preference for a spe-
cific treatment arm by the parents, declining birth
rates (a worldwide trend), premature birth of the
infant, lack of a recruitment tracking tool at the start
of the study, lack of local or regional diabetes regis-
tries, parental unwillingness to commit to long-term
follow-up or blood draws from children in the study,
participation of families in another T1D study, vari-
able support from the medical community, and
unrealistic recruitment goals. Identification of men
with T1D who were soon to be fathers was reported
to be much more difficult than identifying pregnant
women diagnosed with T1D or who already had
children with T1D. The challenge that had the
greatest impact in the United States was enactment
of the Health Insurance Portability and Accountabil-
ity Act of 1996 (HIPAA). All covered entities had to
be compliant to the new regulation by 2003, which
occurred during the recruitment phase of the TRIGR
study. The law required that new methods be devel-
oped for recruitment that did not include study
personnel contacting potentially eligible families
directly; progress was slowed as ethics boards inter-
preted the new regulation. We subsequently relied on
physician referrals and brochures/advertisements to
inform families about the study so that those inter-
ested in participating could contact the study center.
Challenges and strategies of retention
The target sample size estimated for TRIGR was
based on the assumption of a dropout rate of no
more than 20%. A unique feature to the TRIGR
study is that the family is reevaluated for eligibility
after delivery of the infant and randomization. Study
coordinators had the delicate task of informing
families of increased T1D risk, based on HLA testing
of the infant, without increasing anxiety and risking
withdrawal or refusal to use the study formula.
Common retention strategies used in TRIGR cen-
ters worldwide are shown in Table 3. Given the
length of time that participants need to be engaged
in the study (minimum of 10 years) and the require-
ment for annual blood sampling, it has been impor-
tant to gain and sustain the trust of the parents as
well as the children as they get older. Our primary
retention strategies involve methods to maintain
regular communication and provide the family with
easy access to the study team and for follow-up vis-
its. The study coordinators arrange study visits at
Table 2. Recruitment strategies used to recruit fathers with T1D and eligible pregnant women
 Interview pregnant women and their partners at antennal clinics in primary care centers and hospitals
 Review medical history of first-degree relatives of pregnant women
 Provide presentations to physicians, nurses, dietitians, and other healthcare staff at obstetrician offices as well as adult and pediatric
endocrinologist offices and in person communication
 Communicated in person with parents of children with T1D who were visiting pediatric endocrinologist offices
 Place articles in magazines that target pregnant women (e.g., fit pregnancy, parenting, prevention) and fathers with diabetes
(diabetes magazines)
 Place TRIGR posters and brochures in men’s washrooms near antenatal clinics
 Place TRIGR posters and brochures in adult endocrinologist offices, gymnasiums, and pharmacies
 Include a photograph of a pregnant woman or a football player with T1Da in study advertisement posters
T1D: type 1 diabetes; TRIGR: Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk.
aPermission was obtained to use photographs.
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the most convenient location for the family, for
example, physician offices, school, other TRIGR cen-
ters, or at home with a nurse or pediatric phleboto-
mist. In the Netherlands, nearly all study procedures
are performed at home. In Australia, home visits
have been essential to retain families who live long
distances from the study center. After the 6-year
visit, parents are provided with autoantibody results
for their child from 18 months to 6 years of age and
receive results annually thereafter. Children are
asked to provide assent to continue in this study,
usually at the age of 7. An ancillary nutrition study
on later consumption of milk and cereal products
began in 2005. Families who consented to the ancil-
lary nutrition study are contacted biannually by the
study center dietitian or coordinator (starting when
the child is 18 months old, for a short dietary inter-
view). The ancillary study has been an effective
method of maintaining contact with the participat-
ing families. Frequent blood sampling from chil-
dren, difficult family situations, and lack of time are
the primary reasons for dropout in TRIGR.
Discussion
The TRIGR study is the first international multicen-
ter randomized clinical trial to address the research
question of whether dietary intervention can pre-
vent T1D. An important aspect of the TRIGR design
was identification of eligible infants either prior to
birth or within 7 days of birth to participate in an
8-month intervention period and a 10-year follow-
up period. Not unique to TRIGR was a lower recruit-
ment rate than projected when the trial was
designed and limited funding for advertisement and
travel for recruitment training. Study center loca-
tions were selected initially when the funding pro-
posal was written. Although all of the initial group
of study investigators have extensive research
experience and clinical practice related to our target
population, for example, endocrinology, obstetrics,
it was difficult to identify additional study centers
with large numbers of prospective participants, that
is, women of childbearing age with T1D. The lack of
national diabetes registries, a worldwide decline in
birth rate, and, in the United States, enactment of
HIPAA made recruitment to this international study
particularly challenging. Nevertheless, TRIGR inves-
tigators and coordinators met our enrollment goal
by continuing recruitment for 2.5 years beyond the
original target date without additional funding.
Recruitment strategies for clinical trials typically
are outlined in the original study protocol, and
country- or center-specific recruitment plans may be
Table 3. Retention strategies used in TRIGR
Communication  Means for families to contact the TRIGR coordinator at all times, for example, 24-h mobile phone TRIGR hotline
 Follow-up telephone calls after each blood sample
 TRIGR websites (country specific)
 Biannual newsletters (country specific and international) – families contributed content
 Dietary interviews during the intervention (monthly) and ancillary nutrition study interviews from 18 months
(biannually)
 TRIGR family meetings
 Informational and motivating letters sent to participants, including dropouts
Easing impact of
blood sampling
 Pain control, that is, use of topical anesthetic creams and distraction techniques; for example, glucose solutions
for infants, Buzzy for pain relief, flash cards, massage
 Home visits from a pediatric phlebotomist/study nurse or scheduling visits at the medical office/laboratory nearest
to the family
 Local laboratories that have a phlebotomist with pediatric experience
Engaging
children
 Art and photography contests; winning artwork, and photographs used for holiday cards, calendars, and
newsletters
 TRIGR crossword puzzle
 Assent of children obtained, usually at 7 years of age
 PowerPoint presentation, ‘Why are they taking my blood’, to help children understand research and what
happens to their samples
 Small gifts; for example, books and games at annual visits
 Birthday/Christmas/Easter cards
Assisting parents  Compensation for travel costs
 Availability of a dietitian and/or doctor to assist families whose children have health problems
 TRIGR calendar to record illnesses, immunizations, appointment dates
 TRIGR dietary advice booklets
 Visit reminder calls and letters
TRIGR: Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk.
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drafted before recruitment begins. We recommend
that recruitment and retention strategies and mate-
rials be developed in detail before recruitment and
enrollment begin and that regular communication
among study coordinators be established early,
facilitated by national coordinators when appropri-
ate, and continued throughout this study to assess
which strategies are most successful and which stra-
tegies should be abandoned and to develop new
strategies based on observed needs and obstacles.
To date, the TRIGR study has experienced a lower
rate of attrition (14%) than that reported by Karlson
and Rapoff [9] (37%) in their review of attrition rates
in randomized interventions in children with
chronic conditions. Our success may be due in part
to the efforts by the study coordinators to avoid
complications with blood samples, that is, decrease
anxiety by administering a topical anesthetic before
blood draws and ensuring that laboratories have
staff skilled in drawing blood from children, and
ease travel requirements for study visits. Our drop-
out rate is also lower than that reported by Janus
and Goldberg [10] (34.5%), who examined attrition
and factors influencing participation in a prospec-
tive study by families with children under 1 year of
age. The reason for dropout they reported, that is,
families being too busy, is consistent with what has
been observed in TRIGR. Innovative strategies to
improve participant understanding of and commit-
ment to the study protocol are necessary for satisfac-
tory enrollment and retention rates and long-term
compliance with the study protocol.
Study coordinators are key to effective recruit-
ment and retention of participants in all clinical
trials. The importance of their role is emphasized in
a clinical trial in which children are enrolled at birth
and followed up for number of years. The trial may
be designed and funding secured by physicians or
others responsible for the clinical aspects of the trial;
however, each coordinator’s personal commitment
and ability to maintain the commitment and inter-
est of parents and children are key to successful
completion of such trials.
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